Clinical trial
(Part A) A Non-randomized, Open, Single-dose Escalation to Evaluate Tolerability and Safety of Single Oral Dose of HY209; (Part B) A Block-randomized, Double-blinded, Placebo-controlled, Multiple-dose Escalation to Evaluate Tolerability and Safety of Multiple Oral Doses of HY209 Phase 1 Clinical Trial in Healthy Volunteers
NCT06533878 is registered in ClinicalTrials.gov with Kukjeon Pharmaceutical Co.,Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- (Part A) A Non-randomized, Open, Single-dose Escalation to Evaluate Tolerability and Safety of Single Oral Dose of HY209; (Part B) A Block-randomized, Double-blinded, Placebo-controlled, Multiple-dose Escalation to Evaluate Tolerability and Safety of Multiple Oral Doses of HY209 Phase 1 Clinical Trial in Healthy Volunteers
- Lead sponsor
- Kukjeon Pharmaceutical Co.,Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- September 13, 2023
- Completion date
- December 31, 2025
- Enrollment
- 59 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.